Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886491 · ClinicalTrials.gov registry record · Phase 1
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study of Leukemia, sponsored by Takeda.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 11
- Study locations
NCT05886491: Active Phase 1 study of Leukemia, sponsored by Takeda.
NCT05886491 is a Phase 1 study of Leukemia that is active but no longer recruiting, run by Takeda. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05886491, a Phase 1 study of Leukemia, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 11
- Study locations
Study Summary
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
Conditions Studied
Interventions
- DRUG GDX012
- DRUG Chemotherapy Agents
Study Locations (11)
Alabama
- University of Alabama at Birmingham (UAB) Hospital - Birmingham
California
- City of Hope - Duarte
Colorado
- Sarah Cannon/CBCI - Denver
Illinois
- Comprehensive Cancer Center of Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University - St Louis
New York
- Thomas Jefferson University - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2026-05-12 |
| Phase | Phase 1 |
What the registry record for NCT05886491 still lists
NCT05886491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which GDX012 is the first listed.
NCT05886491 lists 11 locations in 11 states (Alabama, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05886491 about?
NCT05886491 is a clinical study titled "A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia". GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
What is the current status of trial NCT05886491?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-07-11. Estimated completion is 2026-05-12.
What conditions does trial NCT05886491 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT05886491?
The interventions under investigation include: GDX012 (DRUG), Chemotherapy Agents (DRUG).
Who is sponsoring clinical trial NCT05886491?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05886491 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05886491's enrollment target sits among peer trials
16 195th of 233 higher than 31 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI